[Abstract Only] Randomized trial: Once-daily, subcutaneous vosoritide therapy in children with achondroplasia

Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial – The Lancet

Commentary: New drug shown to improve bone growth in children with achondroplasia in global phase III trial – Murdoch Children’s Research Institute

Commentary on Twitter

NEW Research—Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial https://t.co/LbknV5D2yL pic.twitter.com/KQvRoC58pb

— The Lancet (@TheLancet) September 7, 2020